ASCO Genitourinary Cancers Symposium


 

ASCO GU 2022 Efficacy & Safety of Continuing Enza in Chemo-Naïve mCRPC Patients Treated With Docetaxel + Prednisolone Who Have Progressed on Enza: Phase 3b PRESIDE Study

65 views
February 24, 2022
0 Comments
Login to view comments. Click here to Login